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a b s t r a c t
Pre-steady state kinetic analysis of mechanistic features of substrate binding and processing is crucial for
insight into the evolution of inhibitor-resistant forms of HIV-1 protease. These data may provide a correct
vector for rational drug design assuming possible intrinsic dynamic effects. These data should also give
some clues to the molecular mechanism of protease action and resistance to inhibitors. Here we report
pre-steady state kinetics of the interaction of wild type or mutant forms of HIV-1 protease with a FRET-
labeled peptide. The three-stage “minimal” kinetic scheme with ﬁrst and second reversible steps of
substrate binding and with following irreversible peptide cleavage step adequately described experi-
mental data. For the ﬁrst time, a set of “elementary” kinetic parameters of wild type HIV-1 protease and
its natural mutant inhibitor-resistant forms MDR-HM, ANAM-11 and prDRV4 were compared. Inhibitors
of the ﬁrst and second generation were used to estimate the inhibitory effects on HIV-1 protease activity.
The resulting set of kinetic data supported that the mutant forms are kinetically unaffected by inhibitors
of the ﬁrst generation, proving their functional resistance to these compounds. The second generation
inhibitor darunavir inhibited mutant forms MDR-HM and ANAM-11, but was ineffective against prDRV4.
Our kinetic data revealed that these inhibitors induced different conformational changes in the enzyme
and, thereby they have different mode of binding in the enzyme active site. These data conﬁrmed hy-
pothesis that the driving force of the inhibitor-resistance evolution is disruption of enzyme-inhibitor
complex by changing of the contact network in the inhibitor binding site.
© 2017 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights
reserved.
1. Introduction
HIV-1 protease (PR) remains an important pharmaceutical target.
The enzyme is a member of the aspartic protease family and has an
active site characterized by a deep substrate-binding pocket and two
ﬂexible gate loops, called FLAPs. The mechanistic events describing
binding and processing of PR substrates are crucially important for
thedesignof novel inhibitors. At present, numerous crystal structures
of the substrate- and inhibitor-boundprotease are available clarifying
themolecularmechanismof drug resistance [1]. Alongsidewith static
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